Randomized Controlled Trial
Copyright ©The Author(s) 2016.
World J Hepatol. Feb 28, 2016; 8(6): 331-339
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331
Table 3 Sustained virologic response at follow-up week 24 in the crossover group n (%)
SVR
Total19/27 (70.4)
TN TW12 failure (< 2 log decline HCV RNA)8/11 (72.7)
TE TW12 failure (detectable HCV RNA)11/16 (68.8)
TN TW24 failure (detectable HCV RNA)0/0